FDA Brief

Warning letters Drugs

FDA warning letter to

Ariella Naturals

High riskIssued Aug 4, 2022Posted Aug 9, 2022Center for Drug Evaluation and Research | CDER

FDA warned Ariella Naturals that its website sells unapproved mole and skin tag removal drugs without FDA approval.

What happened

In August 2022, FDA reviewed tryariella.com and found the company takes orders for two Ariella skin tag and mole removal products. FDA said website claims, including before-and-after photos and promises that skin tags or moles fall off in days to weeks, show the products are intended to treat disease or affect the body. FDA said there are no legally marketed OTC drugs for mole or skin tag removal and warned that self-treatment can delay cancer diagnosis and cause injuries or scarring.

What FDA found

  1. The products are drugs because the website claims they remove skin tags and moles and affect the body.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. The products are new drugs because they are not generally recognized as safe and effective for those uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. The products were offered for sale without an FDA-approved application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)

What FDA wants

FDA asks the company to notify it in writing within fifteen working days of receipt, describing steps taken to address the violations and prevent recurrence, with related documentation. If corrective actions cannot be completed in that time, the company must state the reason and the time within which it will do so.

Who should pay attention

  • online sellers of skin-care and beauty products
  • companies marketing mole or skin-tag removal products
  • regulatory teams reviewing website claims for drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk